SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
6 references·0 citing·26 second hop
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective (2020)Current challenges for assessing the long…Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations (2019)Estimating Lifetime Benefits …Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study (2018)Survival Extrapolation in Can…Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making (2018)Real world data: an opportuni…Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies (2017)Using Real-World Data in Heal…Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation (2017)Modelling the Survival Outcom…Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data (2013)Survival Analysis for Economi…Cost-Effectiveness in Health and Medicine (1996)Decision Modelling For Health Economic Evaluation (2006)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Planning for Long-Term Follow-Up: Strategies Learned from Longitudinal Studies (2015)Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling (2016)Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? (2020)Accounting for Cured Patients in Cost-Effectiveness Analysis (2016)Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods (2016)Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes (2019)How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness (2019)The Measurement of Observer Agreement for Categorical Data (1977)Methods for the economic evaluation of health care programmes (1987)Methods for the Economic Evaluation of Health Care Programmes (2005)The Role of Digital Strategies in Financing Health Care for Universal Health Coverage in Low- and Middle-Income Countries (2018)Real World Data in Health Technology Assessment of Complex Health Technologies (2022)Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process (2024)Which clinical studies provide the best evidence? (2000)Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions (2002)Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report (2007)Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics (2020)Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration (2020)Use of Real‐World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019 (2021)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Novel and existing flexible survival methods for network meta-analyses (2022)A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement (2019)Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma (2021)
this work references cited by second hop

References

  • 2013Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data541 cited
  • 2018Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making237 cited
  • 2017Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies112 cited
  • 2019Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations94 cited
  • 2018Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study69 cited
  • 2017Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation65 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work